GlassScriptPhysician profile
Alice Ramsey
NPI 1235137662
$2,539.14
in general payments reported to CMS, 2019-2025
26 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $392 · 2021: $435 · 2022: $127 · 2023: $279 · 2024: $568 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461 · Education: $20.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.98 |
| Education | $20.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $469.45 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $397.83 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $355.04 | 2021-2025 | |
| Lilly USA, LLC | $308.15 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $171.76 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $118.16 | 2023-2025 | Gemtesa |
| Mylan Specialty L.P. | $92.27 | 2019-2024 | Yupelri |
| Ge Healthcare | $71.92 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.00 | 2020-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $55.47 | 2020-2021 | |
| Astellas Pharma US INC | $49.87 | 2019-2023 | Veozah |
| Allergan, INC. | $45.26 | 2019-2020 | |
| Novo Nordisk INC | $42.08 | 2020-2021 | |
| Ibsa Pharma INC. | $37.69 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $37.17 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $35.76 | 2023-2024 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $26.78 | 2023 | Auvelity |
| Phathom Pharmaceuticals, INC. | $26.62 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.10 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $23.36 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $13.52 | 2022 | |
| Abbott Laboratories | $12.46 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.80 | 2019 | |
| Genentech USA, INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Ramsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.